References
[1]. Dai, F., et al., Lack of association between pretreatment glutamate/GABA and major depressive disorder treatment response. Transl Psychiatry, 2025. 15(1): p. 71.
[2]. Tette, F.M., S.K. Kwofie, and M.D. Wilson, Therapeutic Anti-Depressant Potential of Microbial GABA Produced by Lactobacillus rhamnosus Strains for GABAergic Signaling Restoration and Inhibition of Addiction-Induced HPA Axis Hyperactivity. Curr Issues Mol Biol, 2022. 44(4): p. 1434-1451.
[3]. Zhang, Q., et al., Insights and progress on the biosynthesis, metabolism, and physiological functions of gamma-aminobutyric acid (GABA): a review. PeerJ, 2024. 12: p. e18712.
[4]. Jewett, B.E. and S. Sharma, Physiology, GABA, in StatPearls. 2025, StatPearls Publishing Copyright © 2025, StatPearls Publishing LLC.: Treasure Island (FL).
[5]. Zink, M., et al., Reduced expression of GABA transporter GAT3 in helpless rats, an animal model of depression. Neurochem Res, 2009. 34(9): p. 1584-93.
[6]. Smith, K.M., Hyperactivity in mice lacking one allele of the glutamic acid decarboxylase 67 gene. Atten Defic Hyperact Disord, 2018. 10(4): p. 267-271.
[7]. Nullmeier, S., et al., Glutamic acid decarboxylase 67 haplodeficiency in mice: consequences of postweaning social isolation on behavior and changes in brain neurochemical systems. Brain Struct Funct, 2020. 225(6): p. 1719-1742.
[8]. Gu, S.M., et al., Different development patterns of reward behaviors induced by ketamine and JWH-018 in striatal GAD67 knockdown mice. J Vet Sci, 2024. 25(5): p. e63.
[9]. Wang, Z., et al., GABA+ levels in postmenopausal women with mild-to-moderate depression: A preliminary study. Medicine (Baltimore), 2016. 95(39): p. e4918.
[10]. Guimarães, A.P., et al., GABA Supplementation, Increased Heart-Rate Variability, Emotional Response, Sleep Efficiency and Reduced Depression in Sedentary Overweight Women Undergoing Physical Exercise: Placebo-Controlled, Randomized Clinical Trial. J Diet Suppl, 2024. 21(4): p. 512-526.
[11]. Gabbay, V., et al., Anterior cingulate cortex γ-aminobutyric acid deficits in youth with depression. Transl Psychiatry, 2017. 7(8): p. e1216.
[12]. Epperson, C.N., et al., Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program. J Affect Disord, 2023. 320: p. 353-359.
[13]. Deligiannidis, K.M., et al., Zuranolone for the Treatment of Postpartum Depression. Am J Psychiatry, 2023. 180(9): p. 668-675.
[14]. Bosch, O.G., et al., Gamma-hydroxybutyrate enhances mood and prosocial behavior without affecting plasma oxytocin and testosterone. Psychoneuroendocrinology, 2015. 62: p. 1-10.
[15]. Bruijn, J.A., et al., Trait anxiety and the effect of a single high dose of diazepam in unipolar depression. J Psychiatr Res, 2001. 35(6): p. 331-7.
[16]. Laws, D., J.J. Ashford, and J.A. Anstee, A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice. Acta Psychiatr Scand, 1990. 81(2): p. 185-9.
Cite this article
Chen,S. (2025). Revealing GABA Induced Depression: Dual Validation of Animal Experiments and Clinical Data. Theoretical and Natural Science,117,8-13.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of ICBioMed 2025 Symposium: Computational Modelling and Simulation for Biology and Medicine
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).
References
[1]. Dai, F., et al., Lack of association between pretreatment glutamate/GABA and major depressive disorder treatment response. Transl Psychiatry, 2025. 15(1): p. 71.
[2]. Tette, F.M., S.K. Kwofie, and M.D. Wilson, Therapeutic Anti-Depressant Potential of Microbial GABA Produced by Lactobacillus rhamnosus Strains for GABAergic Signaling Restoration and Inhibition of Addiction-Induced HPA Axis Hyperactivity. Curr Issues Mol Biol, 2022. 44(4): p. 1434-1451.
[3]. Zhang, Q., et al., Insights and progress on the biosynthesis, metabolism, and physiological functions of gamma-aminobutyric acid (GABA): a review. PeerJ, 2024. 12: p. e18712.
[4]. Jewett, B.E. and S. Sharma, Physiology, GABA, in StatPearls. 2025, StatPearls Publishing Copyright © 2025, StatPearls Publishing LLC.: Treasure Island (FL).
[5]. Zink, M., et al., Reduced expression of GABA transporter GAT3 in helpless rats, an animal model of depression. Neurochem Res, 2009. 34(9): p. 1584-93.
[6]. Smith, K.M., Hyperactivity in mice lacking one allele of the glutamic acid decarboxylase 67 gene. Atten Defic Hyperact Disord, 2018. 10(4): p. 267-271.
[7]. Nullmeier, S., et al., Glutamic acid decarboxylase 67 haplodeficiency in mice: consequences of postweaning social isolation on behavior and changes in brain neurochemical systems. Brain Struct Funct, 2020. 225(6): p. 1719-1742.
[8]. Gu, S.M., et al., Different development patterns of reward behaviors induced by ketamine and JWH-018 in striatal GAD67 knockdown mice. J Vet Sci, 2024. 25(5): p. e63.
[9]. Wang, Z., et al., GABA+ levels in postmenopausal women with mild-to-moderate depression: A preliminary study. Medicine (Baltimore), 2016. 95(39): p. e4918.
[10]. Guimarães, A.P., et al., GABA Supplementation, Increased Heart-Rate Variability, Emotional Response, Sleep Efficiency and Reduced Depression in Sedentary Overweight Women Undergoing Physical Exercise: Placebo-Controlled, Randomized Clinical Trial. J Diet Suppl, 2024. 21(4): p. 512-526.
[11]. Gabbay, V., et al., Anterior cingulate cortex γ-aminobutyric acid deficits in youth with depression. Transl Psychiatry, 2017. 7(8): p. e1216.
[12]. Epperson, C.N., et al., Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program. J Affect Disord, 2023. 320: p. 353-359.
[13]. Deligiannidis, K.M., et al., Zuranolone for the Treatment of Postpartum Depression. Am J Psychiatry, 2023. 180(9): p. 668-675.
[14]. Bosch, O.G., et al., Gamma-hydroxybutyrate enhances mood and prosocial behavior without affecting plasma oxytocin and testosterone. Psychoneuroendocrinology, 2015. 62: p. 1-10.
[15]. Bruijn, J.A., et al., Trait anxiety and the effect of a single high dose of diazepam in unipolar depression. J Psychiatr Res, 2001. 35(6): p. 331-7.
[16]. Laws, D., J.J. Ashford, and J.A. Anstee, A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice. Acta Psychiatr Scand, 1990. 81(2): p. 185-9.